Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882807 | ISIN: US92532F1003 | Ticker-Symbol: VX1
Tradegate
04.07.25 | 12:18
388,65 Euro
-0,47 % -1,85
1-Jahres-Chart
VERTEX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VERTEX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
386,45388,8512:30
386,10388,6012:30

Aktuelle News zur VERTEX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoVertex Presents Durable CRISPR Therapy Benefits In Sickle Cell And Thalassemia308CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals (VRTX), Thursday reported compelling long-term data for its CRISPR/Cas9 gene-edited therapy, PrCASGEVY, at the EHA Congress. In sickle...
► Artikel lesen
MiVertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek9
MiVertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold4
DiSodium channel blockers for pain: New opportunities after Vertex's 'watershed' moment11
DiVertex's new cystic fibrosis treatment approved in EU5
DiVertex Pharmaceuticals Incorporated: Vertex Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis221- ALYFTREK(deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for...
► Artikel lesen
VERTEX PHARMACEUTICALS Aktie jetzt für 0€ handeln
Di$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today8
27.06.Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug26
24.06.ADA: Vertex closer to weaning type 1 diabetics off insulin13
23.06.Vertex Pharma's Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence33
23.06.Vertex's remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test15
23.06.Vertex and Ono Pharmaceutical form exclusive alliance for Povetacicept in Japan and South Korea17
21.06.Vertex bei ADA 85. Wissenschaftstagung: Vielversprechender Durchbruch bei Diabetes27
21.06.Vertex posts additional trial data for type 1 diabetes therapy22
20.06.Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake8
18.06.Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives29
17.06.A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 10 Analysts13
11.06.Vertex lays off 125 staffers, slims Rhode Island campus after ditching failed diabetes cell-device combo13
10.06.$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today7
09.06.How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?10
Weiter >>
194 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,3,10